A. Basavapathruni

发表

Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.

Julian Tirado-Rives, William L Jorgensen, W. L. Jorgensen, 2006, Bioorganic & medicinal chemistry letters.

Mechanism of Action of (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)thymine as an anti-HIV agent

Christopher M. Bailey, M. Otto, K. Anderson, 2007, Antiviral chemistry & chemotherapy.

Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis.

R. Copeland, A. Basavapathruni, M. Moyer, 2011, Analytical biochemistry.

Envelope Vaccination Shapes Viral Envelope Evolution following Simian Immunodeficiency Virus Infection in Rhesus Monkeys

B. Korber, P. Hraber, J. Mascola, 2009, Journal of Virology.

Envelope Vaccination Shapes Viral Envelope Evolution following Simian Immunodeﬁciency Virus Infection in Rhesus Monkeys (cid:1)

B. Korber, P. Hraber, J. Mascola, 2009 .

Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate.

W. Hinz, K. Anderson, D. Austin, 2013, Bioorganic & medicinal chemistry letters.

Defining a Molecular Mechanism of Synergy between Nucleoside and Nonnucleoside AIDS Drugs*

Christopher M. Bailey, K. Anderson, A. Basavapathruni, 2004, Journal of Biological Chemistry.

Chiral synthons via chloroperoxidase catalysis

A. Basavapathruni, F. Lakner, L. Hager, 1998 .

Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL-Rearranged Leukemia.

E. Olhava, Lei Jin, R. Copeland, 2012 .

Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L

Tim J. Wigle, E. Olhava, Lei Jin, 2012, Chemical biology & drug design.

Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases.

K. Anderson, A. Basavapathruni, E. Murakami, 2005, Antiviral research.

Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations.

Christopher M. Bailey, K. Anderson, M. de Béthune, 2006, Biochemistry.

Mechanistic Studies to Understand the Progressive Development of Resistance in Human Immunodeficiency Virus Type 1 Reverse Transcriptase to Abacavir*

K. Anderson, A. Ray, A. Basavapathruni, 2002, The Journal of Biological Chemistry.

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Robert A Copeland, Nigel J Waters, E. Olhava, 2013, Blood.

Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis.

K. Anderson, R. Schinazi, C. K. Chu, 2003, Biochemistry.

Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.

William L Jorgensen, Christopher M. Bailey, W. L. Jorgensen, 2006, Bioorganic & medicinal chemistry letters.

Probing the Mechanistic Consequences of 5-Fluorine Substitution on Cytidine Nucleotide Analogue Incorporation by HIV-1 Reverse Transcriptase

K. Anderson, R. Schinazi, C. K. Chu, 2003, Antiviral chemistry & chemotherapy.

Reverse transcription of the HIV‐1 pandemic

A. Basavapathruni, K. Anderson, 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors.

Christopher M. Bailey, K. Anderson, M. Petersen, 2008, Bioorganic & medicinal chemistry.

[d4U]-butyne-[HI-236] as a non-cleavable, bifunctional NRTI/NNRTI HIV-1 reverse-transcriptase inhibitor.

Christopher M. Bailey, K. Anderson, A. Basavapathruni, 2007, Bioorganic & medicinal chemistry letters.

Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitor

Robert A Copeland, Nigel J Waters, Lei Jin, 2014, Biopharmaceutics & drug disposition.

Characterization of the Enzymatic Activity of SETDB1 and Its 1:1 Complex with ATF7IP.

Jodi Gureasko, T. Riera, R. Copeland, 2016, Biochemistry.

Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.

Nigel J Waters, E. Olhava, N. Waters, 2015, Journal of controlled release : official journal of the Controlled Release Society.

Envelope Variable Region 4 Is the First Target of Neutralizing Antibodies in Early Simian Immunodeficiency Virus mac251 Infection of Rhesus Monkeys

J. Mascola, N. Letvin, G. Nabel, 2012, Journal of Virology.

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

E. Olhava, Lei Jin, R. Copeland, 2013, Blood.

Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.

N. Waters, R. Pollock, A. Basavapathruni, 2015, Journal of controlled release : official journal of the Controlled Release Society.

Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L

Lei Jin, R. Copeland, R. Pollock, 2012, Chemical biology & drug design.